Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.
Publication/Presentation Date
8-1-1994
Abstract
The treatment of primary central nervous system lymphoma with chemotherapy prior to whole-brain radiation therapy (WBRT) has improved outcome considerably in this previously fatal disease. Complete or partial responses to intravenous methotrexate (3.5 gm/sq m with leucovorin rescue every 3 weeks for two to four cycles) were seen in 12 of 13 patients originally treated. A total of 25 patients (including the original 13) have now been treated with one to six cycles of methotrexate every 10 to 21 days prior to WBRT. Twenty-two had partial or complete responses, with a median duration of response of 32 months. Median survival time was 33 months (42.5 months in those responding to therapy). Nine patients are alive and without evidence of disease 9 to 122 months following therapy. Acute and long-term toxicities were minimal. Systemic methotrexate administration prior to WBRT is well tolerated and produces long-term survival.
Volume
81
Issue
2
First Page
188
Last Page
195
ISSN
0022-3085
Published In/Presented At
Glass, J., Gruber, M. L., Cher, L., & Hochberg, F. H. (1994). Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. Journal of neurosurgery, 81(2), 188–195. https://doi.org/10.3171/jns.1994.81.2.0188
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
8027800
Department(s)
Administration and Leadership
Document Type
Article